相关实验视频
Updated: Jan 9, 2026
01:27
Pulmonary Embolism III: Nursing Management
Published on: June 19, 2025
320
ING2 PHD 域将基因组 H3 lysine 4 甲基化与活性基因抑制联系起来
Xiaobing Shi1, Tao Hong, Kay L Walter
1Department of Biological Sciences, Stanford University, Stanford, California 94305, USA.
Nature
|May 27, 2006
概括
三甲基化组织素H3 lysine 4 (H3K4me3) 可以积极抑制基因表达. ING2蛋白与H3K4me3结合,稳定了基因促进器的抑制复合体,影响了DNA损伤反应和瘤抑制.
科学领域:
- 表观遗传学和分子生物学
- 染色体生物学 染色体生物学
- 基因规则 基因规则
背景情况:
- 核过程的动态调节涉及到共价色素修饰.
- 基因组H3氨酸4甲基化 (H3K4me) 与 euchromatic 区域和基因表达有关.
- H3K4可以是单基,二基或三基甲基化,与H3K4me3相关的活性基因.
研究的目的:
- 确定结合甲基化H3K4.4的新型效应因子域.
- 调查ING家族蛋白质在H3K4甲基化识别中的作用.
- 阐明H3K4me3在基因抑制和细胞对DNA损伤反应中的功能.
主要方法:
- 甲基化H3K4效应域的识别和表征.
- 生物化学分析以确定ING PHD域与H3K4me2和H3K4me3.3的结合亲和力.
- 分析ING2在mSin3a-HDAC1复合体中的作用以及DNA损伤后的基因表达.
主要成果:
- ING (生长抑制剂) 蛋白质的PHD域特别结合H3K4me3和H3K4me2.
- 作为一个压制性复合体的一部分,ING2表现出与H3K4me3.3的高亲和度结合.
- 在DNA损伤后,ING2-H3K4me3相互作用稳定了DNA增殖基因促进者的抑制复合体,导致基因抑制.
- ING2对基因毒性侮辱反应的调制取决于H3K4me3相互作用.
结论:
- H3K4me3在活性基因抑制中发挥作用,挑战了以前对其功能的看法.
- ING蛋白质,特别是ING2,充当新的H3K4me3读者,将活性标记与基因抑制联系起来.
- 这种涉及H3K4me3和ING2的机制有助于了解瘤抑制功能和细胞对DNA损伤的反应.
相关概念视频
Pulmonary Embolism III: Nursing Management
320
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
320
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
277
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
277
Pulmonary Embolism I: Introduction
464
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
464
Venous Thrombosis III: Interprofessional Care
262
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
262
Pneumothorax-II
852
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
852
Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K